These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 30080059)

  • 1. The influence of anxiety sensitivity on opioid use disorder treatment outcomes.
    Baxley C; Weinstock J; Lustman PJ; Garner AA
    Exp Clin Psychopharmacol; 2019 Feb; 27(1):64-77. PubMed ID: 30080059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal.
    D'Onofrio G; Herring AA; Perrone J; Hawk K; Samuels EA; Cowan E; Anderson E; McCormack R; Huntley K; Owens P; Martel S; Schactman M; Lofwall MR; Walsh SL; Dziura J; Fiellin DA
    JAMA Netw Open; 2024 Jul; 7(7):e2420702. PubMed ID: 38976265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment.
    Rudolf G; Walsh J; Plawman A; Gianutsos P; Alto W; Mancl L; Rudolf V
    Am J Drug Alcohol Abuse; 2018; 44(3):302-309. PubMed ID: 28795846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Worries About Discontinuing Buprenorphine Treatment: Scale Development and Clinical Correlates.
    Stein MD; Conti MT; Herman DS; Anderson BJ; Bailey GL; Noppen DV; Abrantes AM
    Am J Addict; 2019 Jul; 28(4):270-276. PubMed ID: 30993833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model.
    Northrup TF; Stotts AL; Green C; Potter JS; Marino EN; Walker R; Weiss RD; Trivedi M
    Addict Behav; 2015 Feb; 41():20-8. PubMed ID: 25282598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single high-dose buprenorphine for opioid craving during withdrawal.
    Ahmadi J; Jahromi MS; Ghahremani D; London ED
    Trials; 2018 Dec; 19(1):675. PubMed ID: 30526648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association of pain impact and sleep disruption with opioid withdrawal during opioid-use disorder treatment.
    Ellis JD; Han D; Mayo J; Hobelmann JG; Finan PH; Huhn AS
    Br J Clin Pharmacol; 2024 Jun; 90(6):1408-1417. PubMed ID: 38417973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of depression on opioid withdrawal symptoms among smokers with opioid use disorder receiving medication-assisted opioid detoxification.
    Abarno CN; Chapman HM; Copeland AL
    Exp Clin Psychopharmacol; 2023 Apr; 31(2):370-377. PubMed ID: 36074624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compliance with buprenorphine medication-assisted treatment and relapse to opioid use.
    Tkacz J; Severt J; Cacciola J; Ruetsch C
    Am J Addict; 2012; 21(1):55-62. PubMed ID: 22211347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine.
    Malcolm BJ; Polanco M; Barsuglia JP
    J Psychoactive Drugs; 2018; 50(3):256-265. PubMed ID: 29608409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approach to buprenorphine use for opioid withdrawal treatment in the emergency setting.
    Cisewski DH; Santos C; Koyfman A; Long B
    Am J Emerg Med; 2019 Jan; 37(1):143-150. PubMed ID: 30355476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
    Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
    J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Interim Buprenorphine Treatment for opioid use disorder among emerging adults.
    Peck KR; Ochalek TA; Badger GJ; Sigmon SC
    Drug Alcohol Depend; 2020 Mar; 208():107879. PubMed ID: 31991327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.
    Fox AD; Maradiaga J; Weiss L; Sanchez J; Starrels JL; Cunningham CO
    Addict Sci Clin Pract; 2015 Jan; 10(1):2. PubMed ID: 25592182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CE: Acute Pain Management for People with Opioid Use Disorder.
    Broglio K; Matzo M
    Am J Nurs; 2018 Oct; 118(10):30-38. PubMed ID: 30211703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Perceived Role of Withdrawal in Maintaining Opioid Addiction among Adults with Untreated Opioid Use Disorder: A Survey of Syringe Exchange Program Participants.
    Hall OT; Entrup P; Farabee K; Qin H; Rizvi H; Rausch J; Felkel WC; Teater J
    Subst Use Misuse; 2024; 59(2):312-315. PubMed ID: 37861246
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of buprenorphine and methadone in the treatment of opiate withdrawal: possible advantages of buprenorphine for the treatment of opiate-benzodiazepine codependent patients?
    Reed LJ; Glasper A; de Wet CJ; Bearn J; Gossop M
    J Clin Psychopharmacol; 2007 Apr; 27(2):188-92. PubMed ID: 17414244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of PDYN 68-bp VNTR polymorphism with sublingual buprenorphine/naloxone treatment and with opioid or alcohol use disorder: Effect on craving, depression, anxiety and age onset of first use.
    Kaya-Akyüzlü D; Özkan-Kotiloğlu S; Yalçın-Şahiner Ş; Ağtaş-Ertan E; Özgür-İlhan İ
    Eur J Pharmacol; 2022 Apr; 921():174862. PubMed ID: 35271823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative Urgency Linked to Craving and Substance Use Among Adults on Buprenorphine or Methadone.
    Gonçalves SF; Izquierdo AM; Bates RA; Acharya A; Matto H; Sikdar S
    J Behav Health Serv Res; 2024 Jan; 51(1):114-122. PubMed ID: 37414999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.